The History of Exercise Interventions to Prevent Alzheimer Disease
The duo from Cleveland Clinic discussed the reasons for choosing cycling as part of their newly initiated clinical trial, as well as what has been observed for home-based exercise interventions.
African American Patients With MS Switch to Ocrelizumab Treatment Earlier than Caucasian Patients
Researchers also found that patients with progressive MS had longer disease duration before starting DMTs than those with relapsing MS.
Tumor Necrosis Factor Signaling Inhibition Fails to Prevent or Delay Parkinson Disease
Genetically-index TNF-TNFR1 signaling blockade predicted reduced risk of Crohn disease and ulcerative colitis, and increased multiple sclerosis risk.
The Economic Burden of SMA Prior to Treatment Approvals: Lisa Belter, MPH
The director of research analytics at Cure SMA discussed her research on the economic burden and costs patients with spinal muscular atrophy and their caregivers face.
Human Oligodendrocyte Differences Due to Environmental Signals Rather Than Lineage
Researchers used single-cell RNA sequencing on adult, pediatric, and infant surgical tissues to study oligodendrocyte types in order to better understand multiple sclerosis.
Pegunigalsidase Alfa Demonstrates Efficacy in Phase 3 Fabry Disease Study
Protalix BioTherapeutics intends to report final data on the agent, also known as PRX-102 in the second half of 2021, as well as present those findings at an appropriate medical conference.
High Rates of MS Relapse after TNFα Inhibitor Discontinuation: Spencer Hutto, MD
The fellow of autoimmune neurology at Massachusetts General Hospital discusses the ongoing question about whether the demyelination is an unmasking of disease or consequence of the treatment.
Phase 1b Study of Investigational Parkinson Disease Agent YTX-7739 Announced
Additionally, the therapy’s developer Yumanity Therapeutics announced the results of a single ascending dose study and enrollment in a multiple ascending dose study.
FDA Accepts NDA for FT218 in Treatment of Narcolepsy Symptoms
Avadel’s investigational therapy for excessive daytime sleepiness and cataplexy in narcolepsy has an action date set for October 15, 2021.
Predicting MS Disability With IL-1 Receptor Antagonist Levels: Stephanie Blandford, MSc
The PhD candidate at the neuroimmunology laboratory at Memorial University of Newfoundland discussed her team’s investigations into the use of IL-1RA as a biomarker for MS disability.
NeuroVoices: Dylan Rice, on Improving Adherence to MS DMTs
The clinical research coordinator at Massachusetts General Hospital discussed his presentation from ACTRIMS 2021 on electronic pill bottle monitoring to promote MS medication adherence.
Risdiplam Efficacious in Infants with Spinal Muscular Atrophy Type 1
The FIREFISH clinical trial by PTC Therapeutics is 1 of several studies underway evaluating risdiplam in SMA.
FDA Provides Feedback on NurOwn ALS Therapy, Requests More Data
The recommendation stems from recently published topline data which demonstrated a clinically meaningful treatment response compared to placebo but failed to meet statistical significance.
The Kenneth P. Johnson Memorial Lecture and the Clinical Course of MS: Benjamin Segal, MD
The chair of the Department of Neurology and the director of the Neuroscience Research Institute at The Ohio State University discussed his lecture at ACTRIMS Forum 2021.
Education is Key to Optimum MS Care & Management
June Halper, chief executive officer of the Consortium of Multiple Sclerosis Centers, provides an inside perspective on MS education during MS Awareness Month.
Relivion Noninvasive Neuromodulation System Cleared for Acute Migraine
The headset system from Neurolief was approved based on the findings of a clinical trial of 131 patients with migraine who utilized the device in treatment sessions of up to 1 hour.
Expanding Research in Autoimmune Encephalitis: Divyanshu Dubey, MBBS
The assistant professor of neurology at Mayo Clinic provided his thoughts on the next steps in understanding autoimmune encephalitis and the direction that research must pivot to.
Remote Technology Improves Adherence Rates in Relapsing MS
The authors expanded upon the notion that nonadherence to oral DMTs is more nuanced than simply missing doses.
IL-1RA Biomarker Predicts Disability in Multiple Sclerosis
The researchers found that interleukin-1 receptor antagonist levels in plasma correlated with neurofilament light levels in cerebrospinal fluid.
Cladribine Personalized Dosing Well Tolerated and Efficacious in Multiple Sclerosis
Researchers found that 22 of 23 patients with elevated CSF NfL at baseline had normal levels at 2-year follow-up.
CNM-Au8 as a Novel Therapeutic Category in MS: Robert Glanzman, MD
The chief medical officer at Clene Nanomedicine discussed the recently presented data on CNM-Au8 from the VISIONARY-MS trial.
MS Fatigue Unchanged by Long-Term Programs, Raising Questions About Its Progression
The authors noted that future studies evaluating the time course of fatigue in patients with multiple sclerosis are needed.
Unmet Needs in the Multiple Sclerosis Community: Luc Truyen, MD, PhD
The global head of Development and External Affairs-Neuroscience at Janssen Pharmaceutical discussed areas of multiple sclerosis research that need more attention.
This Week on NeurologyLive — March 1, 2021
Here's what is coming soon to NeurologyLive.
Prevalence of Autoimmune Encephalitis: Divyanshu Dubey, MBBS
The assistant professor of neurology at Mayo Clinic detailed his presentation at ACTRIMS 2021 Forum on the rising prevalence of autoimmune encephalitis.
CNM-Au8 Displays Positive Interim Results in Multiple Sclerosis
Clene Nanomedicine’s nanocatalyst agent CNM-Au8 displayed significant improvements in patients with EDSS scores of 2.0 or higher compared to those with EDSS scores of 1.5 or lower.
Early DMT Prescription in Radiologically Isolated Syndrome: Ilena George, MD
The neurologist from Massachusetts General Hospital gave an overview of her study presented at ACTRIMS.
Increasing Prevalence of Early DMT Prescription in Radiologically Isolated Syndrome
Researchers from Massachusetts General Hospital found that DMT-treated patients were, on average, younger than untreated patients.
MS Diagnosis Disclosure and Concealment Associated With Anxiety, Depression
Higher concealment behavior for patients with multiple sclerosis was associated with higher anxiety, but not depression.
Importance of Evaluating Real-World Populations in MS: Allitia DiBernardo, MD
The global head of medical affairs-neurology at Janssen Pharmaceutical provided background on the need for real-world studies and how they can accurately portray a disease community.
